All In Biotech

Investigational drug · Phase 3

BI 1015550

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

29

Any phase or sponsor naming "BI 1015550"

First trial start

2022

Nov 16, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BI 1015550", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lung Diseases, Interstitial
  • Idiopathic Pulmonary Fibrosis

Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "BI 1015550" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 26 on PubMed

Also in development for Lung Diseases, Interstitial

  • TX000045Phase 22 trials

    Tectonic Therapeutic · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.